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Introduction
The nation's spending for prescription drugs has grown dramatically in recent years (see Figure 1) . Even when controlling for general inflation, there has been a dramatic increase in drug spending, especially since the mid-1980s.
A recent study by the Barents Group for the National Institute for Health Care Management (1999) attempted to measure the relative importance of different factors in the growth of drug spending. In general, the study split inflation into two categories: "utilization" effects and "price" effects. Each of these effects were further split between older drugs (drugs that entered the market before 1992) and new drugs (drugs that entered the market in 1992 or later).
As Table 1 indicates, the study reported that increased utilization accounted for about one third of spending growth.
1 If price levels and the mix of prices had not changed between 1993 and 1998, 36 percent of the total spending growth would still have occurred as a result of the increased number of prescriptions. Increased utilization of newer drugs contributed almost twice as much as utilization of older drugs to this increase.
The study found that about two thirds of spending growth from 1993 to 1998 was attributable to price. Of this portion, 22 percentage points were attributable to pure price increases for older drugs. Another 42 percentage points reflected the fact that newer drugs cost more than older drugs: the study estimated that the average 1998 price for drugs introduced in 1992 or later was $71.49 per prescription, compared to $30.47 for previously existing drugs. This difference reflects higher initial introduction prices as well as price increases after introduction.
Thus the Barents study found that the replacement of older drugs by newer, more This paper seeks to fill that gap, i.e. to provide evidence about differences in quality between new and old drugs (prescribed for given conditions). We hypothesize that, in general, new drugs within a class or for a given diagnosis are of higher quality than old drugs, and that this increase may have a number of impacts, including reduced mortality, reduced morbidity, and reduced expenditure on other medical services, such as inpatient stays and emergency room visits
The hypothesis that drug quality is inversely related to drug age is consistent with "quality ladder" models of innovation. Grossman and Helpman (1991, p. 84 ) describe the key features of these models 2 :
Technological progress stems from costly investments undertaken by profitseeking agents. Entrepreneurs…attempt to develop superior versions of [goods that they see on the market]. When successful in the research lab, an innovator creates a new "state of the art" that captures market share at the expense of a previous generation product. Growth will be sustained if commercial R&D remains an economically viable activity so that the average quality of industrial products continues to rise…Innovative goods are better than older products simply because they provide more "product services" in relation to their cost of production.
If the quality of new drugs is higher than that of old drugs, the "quality-adjusted price" of new drugs may be lower than that of old drugs, even though the unadjusted price is higher. Cutler et al (1996) found that the average cost of treating heart-attack patients increased from $11,175 in 1984 to $14,772 in 1991. Most of this increase was due to a shift from older treatment regimens (medical management and catheterization) to newer, more expensive regimens (angioplasty and bypass surgery). While mean treatment cost increased at an average annual rate of 4.5%, life expectancy following a heart attack increased by 8 months-from 62 to 70 months-during this period. Cutler et al showed that if the shift to newer treatment regimens were entirely responsible for the increase in life expectancy, and the value of a life-year is $25,000, then the shift actually reduced the "cost-of-living index"-a far more meaningful measure of inflation than the change in average treatment price-by 1.1% per year.
In this paper, we will analyze prescribed medicine event-level data (linked to person-and condition-level data) from the 1996 Medical Expenditure Panel Survey (MEPS) to provide evidence about the effect of drug age-the number of years since the drug's active ingredient was first approved by the FDA--on mortality, morbidity, and total medical expenditure, controlling for a number of characteristics of the individual and the event.
Methodology
To assess the effect that the age of the drug prescribed for a given condition has on mortality, morbidity, and total medical expenditures incurred to treat the condition, ideally one would like to randomly assign drugs of different ages to patients with that condition, and observe their outcomes and expenditures. Unfortunately, I was unable to conduct a large-scale experiment in which drugs of different ages were randomly assigned to people. Nevertheless, given the nature of the data-generating process and of the data available, I believe that a properly-specified model will enable me to make valid inferences about the effects of drug age.
To evaluate the effect of drug quality, or age, on medical expenditure and outcomes, there must be a significant amount of exogenous, random variation in prescribing behavior. The health economics literature suggests that, in general, medical practice variation is pervasive and sizeable. If 10 doctors saw a patient with given set of symptoms, conditions, and characteristics, it is highly unlikely that they would prescribe the same medications for him. Although practice variation may be undesirable from a medical perspective, it is advantageous econometrically, since it facilitates identification of the effect of drug choice on the variables of interest.
3
It would surely be a mistake, however, to think that all or perhaps even most of the variation in drugs prescribed for a given condition is random, i.e. uncorrelated with attributes of the individual and/or his condition that may influence outcomes and nondrug medical expenditures. If determinants of outcomes and non-drug expenditure are correlated with the age of the drug prescribed and we fail to control for them, we will obtain biased estimates of the effect of drug age on outcomes and expenditures. For example, if more-educated people tend to receive newer drugs and (for unrelated reasons) also tend to have fewer hospital stays, if we don't control for education we will overestimate the effect of drug age on hospital stays.
While omission of some variables (like education) is likely to result in overstatement of the effect of drug age on hospital stays, the omission of others seems likely to result in understatement of this effect. Suppose that, among people with a given medical condition, the most severely ill are both more likely to receive the newest, most expensive, drugs and more likely to be hospitalized. Failure to control for (untreated) severity of illness-which is difficult to do, in practice-would then bias the drug-age coefficient towards zero. The net effect of plausible omitted-variables biases appears to be ambiguous, a priori.
Fortunately, the MEPS data enable us to control for many important attributes of the individual, condition, and prescription that influence outcomes and non-drug expenditures and that may be correlated with drug age. These include sex, age, education, race, income, insurance status (whether the person is covered by private insurance, Medicare, and Medicaid), who paid for the drug, the condition for which the drug was prescribed, how long the person has had the condition, and the number of medical conditions reported by the person. The first approach we will use to determine 3 Significant geographical variation in treatment patterns was first documented by Wennberg and his colleagues (1982) , who studied New England hospital markets. Other investigators have corroborated this finding in many other settings. For example, McPherson et al (1982) documented substantial variation in the use of common surgical procedures in New England, England, and Norway. As Folland et al (2001, p. 216) observe, "differences in treatment patterns across small areas may occur because of physicians' uncertainty and ignorance over the best medical practice."
the ceteris paribus effect of drug age on outcomes and expenditure will be to include, in a very nonrestrictive fashion, all of these factors as covariates in models of the form:
where: While eq.
(1) appears to control for many potentially relevant determinants of Y that may be correlated with AGE_DRUG, the fact that many individuals in the sample have both multiple medical conditions 4 and multiple prescriptions means that we can control for all individual characteristics-both observed and unobserved-by pursuing a second approach. This involves estimating a model that includes "individual effects" (η j 's):
Estimates of the parameter of interest (β) from eq. (2) are based entirely on the withinindividual correlation between Y and AGE_DRUG, not on the between-individual correlation. 5 Suppose a person has two conditions, asthma and hypertension, and is taking medications for both. He may have above-average numbers of hospital stays for both conditions, compared to other individuals with the same conditions. And he may be taking older-than-average drugs for both conditions. But due to the presence of individual effects in eq. (2), this would not make β positive. For β to be positive, it would have to be the case that the condition for which the age of the person's medications were more above average (relative to both individual and condition means)
was the same as the condition for which his hospital stays were more above average.
MEPS data
We will estimate equations (1) and (2) Figure 4 indicates the linkages between events, conditions, and persons. Table 2 shows the number of events, by type, and their associated average expenditures.
As indicated by eqs. (1) and (2), the unit of observation in our analysis is a prescribed-medicine event. The MEPS Prescribed Medicine Event file contains 171,587
observations. The file reveals the amount paid for the prescription, by source of payment, and the National Drug Code, from which we determined (by linking to other pharmaceutical databases) the year in which the active ingredient was first approved by the FDA. Figure 5 depicts the frequency distribution of MEPS prescriptions, by the date the active ingredient was first approved by the FDA. About ¼ of prescriptions consumed were for drugs approved before 1950; more than half of the drugs consumed in 1996
were approved before 1980. Table 3 shows the drug classes with the largest number of prescriptions in 1996.
Over 90% of the prescriptions are linked to exactly one medical condition. 7 The 1996 Medical Conditions file contains summary information about these medical conditions, including:
• When the condition began 
Empirical Results
Estimates of the parameter β from equations (1) and (2) are presented in Table 4 .
We discuss first the estimates of β from eq. The second dependent variable we consider is a mortality indicator: a dummy variable equal to 1 if the person had died by the end of round 3 of the survey, and otherwise equal to zero. The mortality rate in this sample is quite low-only 0.28% (65) of the 23,230 persons died by the end of round 3. This would seem to make it very difficult to detect any effect of drug age on mortality. But recall that the unit of observation in our analysis is a prescription, not a person, and the fraction of observations in which mortality occurs is higher than 0.28%. People with more prescriptions and more conditions have a higher probability of death. As before, this finding is quite consistent with more aggregate (disease-level) evidence I presented in an earlier paper (Lichtenberg (1996) ). In that paper I examined the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians on rates of hospitalization, surgical procedure, mortality, and related variables. The unit of analysis was a (ICD9 2-digit) disease or diagnosis, which we argued is analogous to a product (or industry) in industrial organization economics. We controlled for the presence of "fixed (diagnosis) effects" by analyzing growth rates of the variables, using a database on diagnosis-level inputs and outcomes at two points in time (1980 and 1991 or 1992) . Our principal findings were: (1) The number of hospital stays, bed-days, and surgical procedures declined most rapidly for those diagnoses with the greatest increase in the total number of drugs prescribed and the greatest change in the distribution of drugs. The estimates imply that an increase of 100 prescriptions is associated with The total estimated reduction in non-drug expenditure from a unit decrease in ln(DRUG_AGE) is $71.09. This reduction in non-drug expenditure is much greater than the increase in prescription cost ($18.00), so reducing the age of the drug results in a substantial net reduction in the total cost of treating the condition.
The estimates in the second column of Table , which are based on models that include individual effects, are quite similar, broadly speaking, to the estimates in the first column, which are based on models without individual effects. 9 They also suggest that people consuming new drugs were significantly less likely to experience work-loss days than people consuming old drugs, although the estimated effect is about 30% smaller.
The estimated effect of ln(DRUG_AGE) on total non-drug expenditure to treat the condition is almost identical--$72.22-but the distribution of cost reduction by event type is somewhat different. When individual effects are included, the reduction in inpatient expenditure accounts for an even higher proportion (89%) of the total reduction in nondrug expenditures.
To summarize, estimates of both eq. (1), which controls for many observed characteristics of the person, condition, and prescription, and eq, (2), which controls for all individual attributes (both observed and unobserved), indicate that people taking newer drugs are likely to have significantly lower medical expenditures and have fewer work-loss days than people taking older drugs for the same condition. The first equation also indicates that mortality is lower among people taking newer drugs.
It is sometimes suggested that, because generic drugs tend to be less expensive than branded drugs, allowing people to use only generic drugs might be an effective means of reducing health expenditure. As the following table shows, generic drugs tend to be much older than branded drugs. 
% of prescriptions mean age (in years) in 1996

Conclusions
The nation's spending for prescription drugs has grown dramatically in recent years.
Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not attempt to measure how much of the difference between new and old drug prices reflects changes in quality as better, newer drugs replace older, less effective medications.
In this paper, we analyzed prescribed medicine event-level data (linked to person-and condition-level data) from the 1996 Medical Expenditure Panel Survey (MEPS) to provide evidence about the effect of drug age on mortality, morbidity, and total medical expenditure, controlling for a number of characteristics of the individual and the event. (Previous researchers have hypothesized that differences in treatment patterns across individuals and areas may occur because of physicians' uncertainty and ignorance over the best medical practice.) The MEPS data enable us to control for many important attributes of the individual, condition, and prescription that influence outcomes and non-drug expenditures and that may be correlated with drug age. These include sex, age, education, race, income, insurance status, who paid for the drug, the condition for which the drug was prescribed, how long the person has had the condition, and the number of medical conditions reported by the person. Indeed, the fact that many individuals in the sample have both multiple medical conditions and multiple prescriptions means that we can control for all individual characteristics-both observed and unobserved-by including "individual effects".
The results provide strong support for the hypothesis that the replacement of older by newer drugs results in reductions in mortality, morbidity, and total medical expenditure. Although the mortality rate in this sample is quite low-making it difficult to detect any effect of drug age on mortality-we found that people consuming new drugs were significantly less likely to die by the end of the survey than people consuming older drugs. As to morbidity, we found that people consuming new drugs were significantly less likely to experience work-loss days than people consuming old drugs, although the estimated effect was not very large.
The estimates indicated that reductions in drug age tend to reduce all types of non-drug medical expenditure, although the reduction in inpatient expenditure is by far the largest. The total estimated reduction in non-drug expenditure from reducing the age of the drug is almost four times as large as the increase in drug expenditure, so reducing the age of the drug results in a substantial net reduction in the total cost of treating the condition.
It is sometimes suggested that, because generic drugs tend to be less expensive than branded drugs, allowing people to use only generic drugs might be an effective means of reducing health expenditure. However generic drugs tend to be much older than branded drugs, and our estimates indicate that denying people access to branded drugs would increase total treatment costs, not reduce them, and would lead to worse outcomes. Table 2 Frequency of and expenditure on MEPS events Estimates of β β (the coefficient on ln(DRUG_AGE)) from eqs. (1) and (2) (t-statistics in parentheses)
